Novartis | NVS - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
AbbVie USD 3.63B 54M 2026-06
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bausch Health Companies USD 901M 88M 2026-06
Biogen USD 709.7M 155.4M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Canopy Growth CAD 31.17M 2.27M 2026-03
Corcept Therapeutics USD 156.9M 28.85M 2026-06
Drreddys Laboratories INR 14.47B 12.45B 2026-03
Eli Lilly USD 3.43B 496M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
J&J USD 6.42B 381M 2026-06
Merck USD 2.89B 219M 2026-06
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 43.3M 13.02M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
Sanofi EUR 2.49B 252M 2026-03
Supernus Pharmaceuticals USD 133.64M 15.41M 2026-06
Zoetis USD 592M 4M 2026-06